News

Objective Capital’s Dr. David Crean to Address Entrepreneurs on Due Diligence Issues

San Diego Startup Week — June 19th – 23rd, 2017

San Diego, CA- June 19, 2017 – Objective Capital Partners, a leading M&A investment banking firm specializing in middle-market M&A and capital raise, healthcare & life sciences and valuation advisory services, is pleased to announce that one of its Managing Directors, David H. Crean, Ph.D., will be a panel speaker as part of San Diego Startup Week on June 19-23, 2017 in San Diego, CA. Dr. Crean will address issues to consider on due diligence from an investment banker’s perspective on June 21, 2017. He will be joined by fellow panelists Jeremy Glaser, Attorney and Partner at Mintz Levin, Brent Grenado, General Partner at Sway Ventures, Patrick Henry, CEO at Quest Fusion, and Walt Tendler, CFO at Mission Venture.

Startup Week brings together entrepreneurs to share progress, exchange resources, and celebrate the thriving innovation community. All efforts are made in bringing together the community to showcase exciting local innovation, share resources, and knowledge, and strengthen connections. For more information about San Diego Startup Week, please visit https://sandiegostartupweek.com.

About San Diego Startup Week
San Diego Startup Week brings together thousands of Southern California’s brightest entrepreneurs, developers, designers, top-tier investors, strategic advisors, community leaders, civic supporters, students, and talent. For more information, visit https://sandiegostartupweek.com/.

About Objective Capital Partners
Objective Capital Partners is a leading M&A investment banking firm whose Principals have collectively engaged in more than 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies. The firm focuses on middle market M&A and capital raise activities for companies with enterprise values between $10-100 million, healthcare & life sciences and valuation advisory services. The firm’s industry expertise includes software and hardware technology, life sciences, business services, IT services, healthcare services, biotech, consumer products and specialized manufacturing. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. Dr. Crean and other Principals of Objective Capital are Registered Representatives of BA Securities. Objective Capital Partners and BA Securities are separate and unaffiliated entities. Additional information on Objective Capital Partners is available at www.objectivecp.com.

Disclosure
This news release is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.

# # #

Objective Capital Partners Contact:
Mandy F. Woods
Business Office Manager
Objective Capital Partners
Tel: 858-208-3442
mandy.woods@objectivecp.com